The meeting will be held in San Francisco, US between 4 and 8 November 2011.
The study intended to assess the efficacy of immune-modulator, recombinant human Interleukin-7 (CYT107).
Recombinant human interleukin-7 (CYT107) is a critical immune-modulator for immune T-cell recovery and enhancement.
CYT107 is added to peginterferon and ribavirin (SOC), for four weeks, in genotype one and four treatment experienced patients defined as nonresponders to SOC.
The treatment has induced a broad immune response associated with HCV viral clearance in genotype one and four patients nonresponders to Peg-IFN and RBV.